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After adjusting for age, gender, blood pressure, smoking status, us& of aspirin and/or 
lipid lowering medication, resting heart rate, and exercise capacity in sequential boot- 
strapping logistic analyses, obesity (i.e.. BMI quintile 5) was independently associated 
wth an abnormal HRR (adjusted odds ratio [OR] 1.66 (1.26 - 2.34) and with CRI 
(adjusted OR 2.23 (1.56 - 3.17). 
Conclusion: Obesity is independently associated with abnormal HRR and with CRI. 
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1158-68 Chronic Subcutaneous Administration of the Cardiac 
Peptide BNP in Experimental Heart Failure Does Not 
Result in the Development of Tolerance to Exogenous 
BNP 
Homa H. Chen John A. Schirger, Alessandro Cataliotti, Gail Hady, John C. Burnett, Jr., 
Mayo Clinic and Foundation, Rochester, MN 
BACKGROUND: Brain natriuretic peptide (BNP) is a cardiac peptide with vasodilating. 
lusitropic, natriuretic and renin-angiotensin-aldosterone (RAAS) inhibiting properties 
which are mediated by the second messenger cGMP. BNP is FDA approved for the man- 
agement acute congestive heart failure (CHF). We have previously shown that chronic 
subcutaneous (SQ) administration of BNP in experimental CHF improves hemodynam- 
its, however, it is unknown if chrome BNP administration leads to the development of tol- 
erance to exogenous BNP. METHODS: We compared the cardiorenal effects of acute 
administration of SQ BNP (*g/Kg) in a group of dogs (n=5) with pacing induced CHF 
(180 bpm for 10 days) to a separate group of CHF dogs (n=6), who received chronic SQ 
BNP @g/Kg) three times a day during10 days of pacing. RESULTS: Chronic SQ BNP 
therapy for 10 days improved cardiac output (3.6r 0.4 vs 2.5* 0.1 Umin) with decreased 
pulmonary capillary wedge pressure (PCWP) (9+ 2 vs 16* 3 mmtig) and systemic vas- 
cular resistance (35* 5 vs 45+ 4 RU) as compared to the untreated group (~~0.05). 
Importantly, acute admlnistration of SQ BNP on day 11, resulted in similar increases in 
plasma cGMP (35+ 5 vs 29* 2 pmolfml) and urinary cGMP excretion (UcGMPV) (6000+ 
1000 vs 4OOOi 600 pmollmin) in both the chronic SQ BNP treated and the untreated 
groups (p>O.O5). These were associated with decreased cardiac filling pressures and 
increased in urine flow, which were also similar in both the chronic SO BNP treated and 
the untreated groups (p>O.O5). CONCLUSION: In this model of experimental CHF, 
chrome SQ BNP administration did not result in the development of tolerance es demon- 
strated by similar increases in plasma cGMP and UcGMPV in the chronic BNP treated 
and the untreated groups with acute administration of SQ BNP. Fwthermore, acute 
administration of SQ BNP resulted in similar decreases in cardiac filling pressures and 
increases in urine flow. This may have important clinical implications, suggesting that 
chronic SQ BNP administration does not lead to the development of tolerance to acute 
BNP administration and suppolting this strategy as efficacious for chronic protein-based 
therapy for CHF. 
1158-69 Chronic Oral Endothelin-A Receptor Antagonism 
Activates the Renin-Angiotensin-System With 
Persisting Sodium Retention in Experimental Heart 
Failure 
John A. Schiraer, Homg H. Chew John C. Burnett, Jr., Mayo Cknic and Foundation, 
Rochester, MN 
Background: Although acute endothelin (ET) receptor antagonism improves systemic 
hemodynamics in congestive hearl failure (CHF). clinical trials with chronic ET receptor 
antagonism reporl exacerbation of CHF symptoms. The mechanisms for this remain 
unclear. Methods: We first defined the temporal activation of the ET and renin-angio- 
tensin-systems (RAS) at the onset of sodium retention I” a canine model of pacing 
induced CHF. Next, we evaluated the effect of chronic oral ET-A receptor antagonism 
(LU135252: started day 3 of pacing) on sodium excretion, glomerular filtration rate and 
neurohumoral activity in canine CHF. Results: Plasma endothelin-1 but not plasma renin 
activity (PRA) increased with the onset of sodium retention in CHF (n=5) compared to 
normal dogs (n=5) (17.Oi2.0 vs 7.0+_ 2.0 pg/mL, ~~0.05). Northern blot analysis demon- 
strated myocardial endothelin-I mRNA activation at the onset of sodium retention (n=5) 
compared to normal dogs (n=5). Myccardial angiotensin II was not activated at this point 
in either group. After 7 days of treatment (n=7) with LU135252 there was no difference in 
sodium retention (73 vs 422 uEqlmin) or glomerular filtration rate vs. untreated CHF 
dogs (n=6). PRA (7~2 vs 1624 nglmlihr, ~~0.05) and plasma endothelin-1 increased 
with treatment. After 16 days of treatment (n=9), despite maintaining glomerular filtration 
rate at normal values, LU135252 did not increase sodium excretion vs. untreated CHF 
dogs (n=E), and PRA tended to further increase with treatment. Conclusion: Activation 
of the ET system precedes activation of the RAS in CHF. ET-A receptor antagonism in 
CHF does not increase sodium excretion but may further activate the RAS. These find- 
ings suggest a mechanism for the exacerbation of CHF symptoms observed in clinical tri- 
als with chronic ET receptor antagonism and support a possible strategy for combining 
antagonism of the ET system and RAS in CHF. 
1158-70 Role of Kinins and Angiotensin II Type 2 Receptors in 
the Cardioprotective Effect of Angiotensin II Type 1 
Receptor Antagonists in Brown Norway Kininogen- 
Deficient Rats 
Yun-He Liu, Xiao-Ping Yang, Ai-Li Yu. Edward G. Shesely, Oscar A. Carretero. Henry 
Ford Hospital, Detroit, Ml 
Background: Previously we reported that lack of kinins influence neither cardiac function 
nor development of HF post-MI; however, klnins play an important role in the cardiopro- 
tective effect of ACEi. Here, we studied the role of kinins and AT, receptors in the protec- 
tive effect of AT,-ant in rats with HF. 
Methods Brown Norway Katholiek (BNK) rats, which are genetically deficient in kinins 
due to a mutation in the klninogen gene, and their wild-type control (BN) underwent 
either sham or coronary artery ligation. 2 months later, they were treated for 2 months 
with a) vehicle, b) AT,-ant (L158609, 1.5 mglkgiday), c) AT,-ant + AT,-ant (PD-123319, 
10 mgikglday), or d) AT,-ant + kinin B, receptor antagonist (icatibant, 100 @@day, in 
BN). We measured left ventricular end-diastolic volume (LVEDV), end-systolic volume 
(ESV) and ejection fraction (EF) by ventnculography, and (interstitial collagen fraction- 
ICF), myocyte cross-sectional area (MCSA ). assessed histologically and heart weight 
(HW). 
Results In BNK, the protective effect of AT, -ant was dimlnished, blockade of AT, recep- 
tors did not influence the effect of AT, -ant on cardiac function and fibrosis; however, it 
blocked the effect of AT,-ant on hypertrophy. and I” BN rats, effect of AT,-ant was 
blocked by ATP-ant. and partially blocked by icatibant. 
Conclusion: 1) AT, receptors acting via kinins play an important role in the cardioprotec- 
tive effect of AT,-ant. 2) the antihypertrophic effect of AT,-ant is mediated by a factor 
other than kinins. 
Effect of AT&ant on cardiac function and remodeling in BN and BNK 
BN BNK 
Sha HF- HF- HF.AT1 ant 
m Vehicle ATlan + AT2ant 
LVEF(%) 64* 25 f 42 f 
1 3(l) 2(2) 
LVEDV 356 646* 562* 
(PI) +29 64(l) 28(2) 
HW (m9/ 254 324+ 264* 
1OOgBW) + 7 12(l) 6(2) 
ICF (%) 4.9 * 10.4 * 6.1 * 
0.3 0.5(l) 0.7(2) 
24 + 2(3) 
656 f 
llO(3) 
314 * 
14(3) 
12.6 * 
1.1(3) 
Sha HF- HF- HF.ATlant 
m Vehicl ATla cATPant 
e nt 
68* 26* 3322 34+3 
1 l(4) 
417 669 * 743 * 761 *52 
*20 49(4) 37 
261 306 * 263 * 323+ 17(6) 
* 7 lO(4) 7(5) 
4.9+ 12.4* ll+ 10 * 0.9 
0.1 l(4) 0.9 
Mean SE; (1) : p < 0.01 versus BN-sham; (2): p < 0.01 versus BN-HF-Vehicle; (3): p 
< 0.001 versus BN-HF.ATl-ant; (4): p < 0.001 versus BNK-sham; (5): p =Z 0.05 
versus BNK-HF-ATl-ant; (6): p < 0.05 versus BNK-HF-ATl-ant. 
